R&D at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's R&D?
- Corvus Pharmaceuticals (CRVS) reported R&D of $11.18M in Q1 2026.
- How has Corvus Pharmaceuticals's R&D changed year-over-year?
- Corvus Pharmaceuticals's R&D increased by 49.9% year-over-year, from $7.45M to $11.18M.
- What is the long-term trend for Corvus Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's R&D has grown at a 3.7% compound annual growth rate (CAGR), from $29.12M to $33.72M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.